Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.
Krug D, Vladimirova V, Untch M, Kühn T, Schneeweiss A, Denkert C, Ataseven B, Solbach C, Gerber B, Tesch H, Golatta M, Seiler S, Heil J, Nekljudova V, Holtschmidt J, Loibl S. Krug D, et al. Among authors: gerber b. Breast. 2024 Apr;74:103701. doi: 10.1016/j.breast.2024.103701. Epub 2024 Feb 24. Breast. 2024. PMID: 38422624 Free PMC article.
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer JU, Seiler S, Denkert C, Tesch H, Jackisch C, Gerber B, Schneeweiss A, Link T, Krug D, Huober J, Rhiem K, Kühn T, Vladimirova V, Nekljudova V, Loibl S. Werutsky G, et al. Among authors: gerber b. Eur J Cancer. 2020 May;130:92-101. doi: 10.1016/j.ejca.2020.02.015. Epub 2020 Mar 13. Eur J Cancer. 2020. PMID: 32179450
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C. Loibl S, et al. Among authors: gerber b. Breast Cancer Res Treat. 2011 Nov;130(2):477-87. doi: 10.1007/s10549-011-1715-8. Epub 2011 Aug 12. Breast Cancer Res Treat. 2011. PMID: 21837479
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. von Minckwitz G, et al. Among authors: gerber b. N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065. N Engl J Med. 2012. PMID: 22276820 Free article. Clinical Trial.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. von Minckwitz G, et al. Among authors: gerber b. J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508812
Response-guided neoadjuvant chemotherapy for breast cancer.
von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S. von Minckwitz G, et al. Among authors: gerber b. J Clin Oncol. 2013 Oct 10;31(29):3623-30. doi: 10.1200/JCO.2012.45.0940. Epub 2013 Sep 3. J Clin Oncol. 2013. PMID: 24002511 Clinical Trial.
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G; German Breast Group Investigators. Gerber B, et al. Ann Oncol. 2013 Dec;24(12):2978-84. doi: 10.1093/annonc/mdt361. Epub 2013 Oct 17. Ann Oncol. 2013. PMID: 24136883 Free article. Clinical Trial.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M. von Minckwitz G, et al. Among authors: gerber b. Ann Oncol. 2014 Jan;25(1):81-9. doi: 10.1093/annonc/mdt410. Epub 2013 Nov 21. Ann Oncol. 2014. PMID: 24273046 Free article. Clinical Trial.
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kümmel S, Huober J, Denkert C, Hilfrich J, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M. Loibl S, et al. Among authors: gerber b. Breast Cancer Res Treat. 2014 Feb;144(1):153-62. doi: 10.1007/s10549-014-2861-6. Epub 2014 Feb 7. Breast Cancer Res Treat. 2014. PMID: 24504379 Free article.
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Loibl S, Untch M. Gerber B, et al. Ann Surg Oncol. 2014 Aug;21(8):2517-24. doi: 10.1245/s10434-014-3606-9. Epub 2014 Apr 18. Ann Surg Oncol. 2014. PMID: 24740826 Clinical Trial.
976 results